Adjuvant testosterone therapy in chronic heart failure (ATTIC): a randomised open-label trial.

ABSTRACT:

Introduction

Heart failure is a major contributor to morbidity and mortality in the geriatric population, with no promising therapy currently available with considerable benefit. Testosterone therapy is an emerging viable treatment option given its beneficial effects, including improving cardiac functional capacity, alleviating symptoms and low cost, among others.

Methods

We have planned an open-label, parallel design, 1:1 randomised controlled trial, which aims to recruit 986 adult males above the age of 60 diagnosed with chronic stable heart failure fulfilling the eligibility criteria. The participants will be randomised into 2 groups of 493 each. Both groups will receive standard recommended treatment regimen of chronic stable heart failure and intervention arm participan

SUBMITTER: Dhar M 

PROVIDER: S-EPMC9157332 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature